Cronos Group: Canaccord Lowers Price Target To $7 Following Poor Results

Last week, Cronos Group (TSX: CRON) reported its second quarter financial results. The company generated $15.62 million in net revenue, an increase of 24% quarter over quarter. Gross profit meanwhile declined more than 100% to -$15.78 million due to Cronos’ cost of sales being higher than their revenue, plus an additional almost $12 million in inventory write-downs. Even though the company had negative gross margins, the company reported positive earnings per share and net income of $0.15 and $70.64 million due to a gain on financial derivatives.

A total of 3 analysts lowered their 12-month price target on Cronos after the earnings, bringing the average price target to C$9.15, down from the C$9.48 it was a day before the earnings. The street high sits at C$14.44 from Raymond James, while the lowest comes in at C$5.90. Cronos has 12 analysts covering the stock, of which 2 have buy ratings, 7 have hold ratings, while 1 analyst has a sell rating and 2 have strong sells on the stock.

Canaccord Genuity was one of the firms to lower their outlook on Cronos, bringing their 12-month price target down to C$7.00, and reiterated their sell rating. The firm cited a lower sales ramp, adjusted EBITDA profitability taking longer, and that the stock price is detached from the fundamentals of the company.

For the quarter, the company’s net revenue came in line with Canaccord’s C$15.58 million estimates. The companies US CBD business declined 8% while it’s Canadian/international revenue increased by 31% quarter over quarter. The company missed completely on its gross margins, which is their seventh (7!) straight quarter of negative gross margins. Operating costs came in roughly $3 million lower than Canaccord had estimated. Cronos had an adjusted EBITDA loss of $49.8 million, which got worse by 34% this quarter, the company also burned $42.31 million and had $1.1 billion of cash on hand.

Below you can see Canaccord’s new fiscal 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Cresco Labs: Consensus First Quarter 2021 Estimates

Cresco Labs (CSE: CL) announced that they will be reporting their first quarter financials before...

Tuesday, May 25, 2021, 11:51:00 AM

Aurora: Canaccord Raises Price Target To $14.00 On Back Of Earnings

Last night, Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported its second quarter 2020 earnings. They...

Friday, February 12, 2021, 04:02:00 PM

Village Farms Gets A Boost From Raymond James

Last Thursday, Raymond James’ increased their 12-month price target on Village Farms (TSX: VFF) (NASDAQ:...

Monday, January 25, 2021, 04:11:28 PM

GAGE Cannabis: PI Financial Reiterates Their Street High Target, Lowers 2021 Estimates

On August 24, Gage Growth Corp. (CSE: GAGE) announced their second quarter financial results. The...

Saturday, August 28, 2021, 11:13:00 AM

Curaleaf: Canccord Slashes Price Target, Anticipates Headwinds For 2022

Earlier this month, Curaleaf Holdings, Inc. (CSE: CURA reported its fourth quarter and full year...

Monday, March 14, 2022, 09:27:00 AM